Epitalon

What Epitalon Does

Epitalon (epithalon, epithalone) is a synthetic tetrapeptide — just four amino acids: Alanine-Glutamate-Aspartate-Glycine. Despite its simplicity, it targets one of the most fundamental mechanisms of aging: telomere shortening. Developed by Professor Vladimir Khavinson over three decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, Epitalon has become the most well-known peptide in the longevity community.

The mechanisms that matter:

• Telomerase activation — Epitalon reactivates telomerase in somatic cells. Telomerase is the enzyme that rebuilds telomeres — the repetitive DNA sequences (TTAGGG) that cap and protect chromosome ends. In most adult cells, telomerase is silenced, and telomeres shorten with each cell division until the cell can no longer divide (replicative senescence). Epitalon reverses this silencing
• Pineal gland regulation — Epitalon was originally derived from pineal gland peptide research. It stimulates melatonin production and normalizes circadian rhythm, particularly in aging individuals whose pineal function has declined
• Antioxidant gene expression — upregulates endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase), reducing oxidative damage that contributes to aging
• Neuroendocrine normalization — restores hormone sensitivity and signaling that deteriorates with age, contributing to improved immune function and stress resilience

The Telomere Theory of Aging

Every time a cell divides, its telomeres shorten by 50–200 base pairs. When telomeres reach a critically short length, the cell enters senescence (stops dividing) or apoptosis (dies). This process is one of the nine recognized hallmarks of biological aging.

Telomerase — the enzyme that rebuilds telomeres — is active in stem cells, immune cells, and reproductive cells, but silenced in most somatic cells after development. Epitalon’s mechanism is to re-engage this enzyme, allowing differentiated cells to maintain their telomere length and continue healthy division.

The promise: If telomere maintenance can be sustained, cells age more slowly, tissues maintain themselves better, and the accumulation of senescent cells (which drive inflammation and dysfunction) is reduced.

The caveat: Telomere shortening is one of nine hallmarks of aging. Even perfect telomere maintenance won’t prevent aging from the other eight mechanisms (mitochondrial dysfunction, epigenetic drift, proteostasis loss, etc.). Epitalon addresses one important factor, not all of them.

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	5–10 mg per day
Frequency	Once daily (evening preferred)
Route	Subcutaneous injection
Cycle length	10–20 days
Cycles per year	2–3
Best timing	Evening (aligns with pineal/melatonin mechanism)

Dose Selection

Protocol	Daily Dose	Cycle Length	Total per Cycle
Conservative	5 mg/day	20 days	100 mg total
Standard	10 mg/day	10 days	100 mg total
Khavinson protocol	10 mg/day	10 days, 2–3x/year	200–300 mg/year

Both protocols deliver the same total dose (~100 mg per cycle). The difference is convenience vs daily exposure time. The 10 mg x 10 day protocol is more common because it’s faster to complete.

Timing

• Evening injection — Epitalon’s pineal gland and melatonin effects align with evening dosing. Many users report improved sleep quality during cycles
• Consistent time — dose at the same time each evening
• No fasting requirement — Epitalon’s mechanism is not dependent on insulin or metabolic state

Reconstitution

For a 10 mg vial — add 1 mL bacteriostatic water:

Daily Dose	Volume to Draw
5 mg	50 units on insulin syringe
10 mg	100 units (full 1 mL)

Concentration: 10 mg/mL. At 10 mg/day, one vial = one day. For a 10-day cycle, you need 10 vials. At 5 mg/day, one vial = two days, so 10 vials for a 20-day cycle.

Storage: Refrigerate reconstituted vials at 2–8°C. Unreconstituted powder is stable at room temperature for months, longer when frozen.

Cycling Structure

Epitalon is unique among peptides — it’s used in short, infrequent bursts rather than chronic dosing:

Year 1 (initial loading):

• Cycle 1: 10 mg/day x 10 days (month 1)
• Cycle 2: 10 mg/day x 10 days (month 4)
• Cycle 3: 10 mg/day x 10 days (month 8)

Maintenance (year 2+):

• 2 cycles per year (every 6 months)
• 10 mg/day x 10 days each

The rationale: Telomerase reactivation doesn’t require continuous stimulation. Each cycle “unlocks” the enzyme for an extended period. The effects of a single cycle persist for months — similar to how a vaccine stimulates an immune response that lasts beyond the injection period.

What to Expect

During the Cycle (Days 1–10)

• Improved sleep quality — the most commonly reported effect. Deeper sleep, more vivid dreams, easier time falling asleep. Attributable to melatonin modulation
• Subtle energy improvement — not stimulant-like, more a general sense of vitality
• Skin quality — some users notice improved skin texture by the end of the cycle
• No dramatic effects — Epitalon works at the cellular level on timescales of months and years. Don’t expect transformation during a 10-day cycle

Between Cycles

• Sleep benefits may persist for weeks to months
• Cellular effects are occurring but not subjectively noticeable
• Telomere length changes require 6–12 months of cycling to potentially measure

Long-Term (Multiple Cycles Over Years)

• Cellular health maintenance — the theoretical benefit is cumulative over years
• Immune function — some longevity practitioners report fewer infections and improved immune markers
• Biological age vs chronological age — the goal is slowing the divergence

What the Research Says

Epitalon has an extensive research base from Khavinson’s group, plus independent confirmations:

Telomerase activation (in vitro): Epitalon treatment of human fetal lung fibroblasts reactivated telomerase, increased telomere length, and extended the number of cell divisions beyond the Hayflick limit (the normal maximum for somatic cells). This is the foundational study. Published in Bulletin of Experimental Biology and Medicine.

Lifespan extension (animal studies): Multiple studies in mice and rats showed Epitalon extended median lifespan by 12–24%. Effects were seen in both healthy animals and tumor-prone strains. In the cancer-prone models, Epitalon actually reduced tumor incidence — suggesting telomere maintenance in immune cells improved cancer surveillance. Published across multiple Russian journals.

Human longevity observations: Khavinson’s group reported improved survival and reduced mortality in elderly patients treated with epithalamin/Epitalon over 6–15 year follow-up periods compared to untreated controls. These are observational studies, not RCTs, and should be interpreted with appropriate caution. Published in Neuroendocrinology Letters.

Melatonin restoration: Epitalon restored melatonin production in aged monkeys and elderly humans whose pineal function had declined. This is relevant because melatonin is not just a sleep hormone — it’s a potent antioxidant with broad anti-aging properties. Published in Advances in Gerontology.

Gene expression: Epitalon modulates expression of genes involved in cell cycle regulation, apoptosis, and antioxidant defense. Microarray studies show activation of protective pathways and suppression of senescence-related genes.

Important caveat: Much of the research comes from Khavinson’s own laboratory, and independent replication at the clinical level is limited. The basic science (telomerase activation, gene expression changes) has been independently confirmed. The human longevity claims remain observational.

Safety

Side Effects

Epitalon has a very clean safety profile across decades of research:

Side Effect	Frequency	Notes
Injection-site irritation	~5%	Mild, transient
Mild drowsiness	~10%	Related to melatonin effect, hence evening dosing
Vivid dreams	~15%	Generally experienced as positive, related to improved REM sleep

No serious adverse events reported in any study. No hormonal disruption. No cardiovascular effects. No hepatotoxicity.

The Cancer Question

Does activating telomerase cause cancer? This is the critical safety question, and the answer is nuanced:

• Cancer cells use telomerase to achieve “immortality” — unlimited replication
• Activating telomerase in normal cells could theoretically promote cancer development
• However, Epitalon appears to normalize telomerase activity, not hyper-activate it
• Animal studies showed reduced tumor incidence in Epitalon-treated groups — possibly because immune cells with maintained telomeres are more effective at cancer surveillance
• No human study has shown increased cancer risk from Epitalon
• The theoretical concern remains, and individuals with active malignancies should not use Epitalon

Practical approach: Epitalon’s short, infrequent cycling (10 days every 4–6 months) limits cumulative exposure. This is fundamentally different from the chronic telomerase activation seen in cancer cells.

Do Not Use If

• Active cancer or history of malignancy (theoretical telomerase concern)
• Pregnant or breastfeeding
• Under 18
• Autoimmune conditions (immunomodulatory effects may be unpredictable)

What Comes Next

• Explore other longevity tools — the Directory has protocols across all categories
• Recovery and repair — BPC-157 Protocol and the Wolverine Stack
• Use the Reconstitution Calculator for exact dosing math